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Abstract
Background: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF)
pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and
delaying median progression free survival in patients with cytokine refractory RCC. However, resistance to therapy
develops at a median of 5 months. In an effort to increase efficacy, we studied the effects of increased sorafenib
dose and intermittent scheduling in a murine RCC xenograft model.
Methods: Mice bearing xenografts derived from the 786-O RCC cell line were treated with sorafenib according to
multiple doses and schedules: 1) Conventional dose (CD) continuous therapy; 2) high dose (HD) intermittent
therapy, 3) CD intermittent therapy and 4) HD continuous therapy. Tumor diameter was measured daily.
Microvessel density was assessed after 3 days to determine the early effects of therapy, and tumor perfusion was
assessed serially by arterial spin labeled (ASL) MRI at day 0, 3, 7 and 10.
Results: Tumors that were treated with HD sorafenib exhibited slowed tumor growth as compared to CD using
either schedule. HD intermittent therapy was superior to CD continous therapy, even though the total dose of
sorafenib was essentially equivalent, and not significantly different than HD continuous therapy. The tumors
exposed to HD sorafenib had lower microvessel density than the untreated or the CD groups. ASL MRI showed
that tumor perfusion was reduced to a greater extent with the HD sorafenib at day 3 and at all time points
thereafter relative to CD therapy. Further the intermittent schedule appeared to maintain RCC sensitivity to
sorafenib as determined by changes in tumor perfusion.
Conclusions: A modification of the sorafenib dosing schedule involving higher dose intermittent treatment
appeared to improve its efficacy in this xenograft model relative to conventional dosing. MRI perfusion imaging
and histologic analysis suggest that this benefit is related to enhanced and protracted antiangiogenic activity. Thus,
better understanding of dosing and schedule issues may lead to improved therapeutic effectiveness of VEGF
directed therapy in RCC and possibly other tumors.
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Recently, several new agents targeting the VEGF pathway
have demonstrated promising activity in patients with
advanced renal cell carcinoma (RCC). Sorafenib is a multi-
tyrosine kinase inhibitor (mTKI) whose targets include
vascular endothelial growth factor receptor-2 (VEGFR2)
and its activity is thought to be based on its inhibition of
this target. In a randomized, placebo-controlled phase III
trial sorafenib prolonged progression free survival (PFS)
from 2.8 months (placebo group) to 5.5 months [1]. Based
on these and other data, sorafenib received FDA approval
for treatment of patients with RCC in late 2005. This
mechanism is particularly relevant in kidney cancer as
opposed to other cancer types (e.g., HCC) where the inhi-
bition of the serine-threonine kinase Raf is likely at least as
important as the inhibition of VEGFR-2.
While these effects are highly significant, strategies to
prolong the effects of sorafenib and other VEGFR TKI
targeted agents are important as tumors typically
develop resistance to therapy within 5-11 months.
Efforts to enhance the efficacy of VEGFR TKIs have
included dose intensification based on either tolerance
[2], pharmacokinetic or pharmocodynamic markers
[3-5]; the use of agents that more selectively inhibit the
VEGFR (eg. Axitinib, tivozonib)[6] combination regi-
mens, sequencing of agents and schedule alterations [7].
Patients exhibiting diseaset h a tp r o g r e s s e do ns o r a f e -
nib have been shown to respond to increased dose of
sorafenib or the administration of sunitinib or the more
selective VEGFR inhibitor axitinib [8,9] suggesting that
the resistance to VEGFR targeted therapy could be over-
come by more intensive inhibition of the target.
Sunitinib is typically administered in a 4 week on/2
week off schedule while sorafenib and pazopanib are
administered continuously. This 2 week break in the
approved sunitinib regimen was instituted to allow for
patients to recover from toxicity of the 50 mg/day dose.
It has been observed that some patients exhibit disease
progression during this break only to later to have their
disease symptoms controlled again with re-initiation of
treatment (Atkins, M. Personal observation). This led to
the development of a 37.5 mg/day continuous sunitinib
regimen. However, this regimen appeared to be less
active than the intermittent schedule in a preliminary
phase II trial [10]. This observation was confirmed in a
phase III trial which established that the lower dose
continuous schedule had an inferior time to disease
deterioration relative to the standard higher dose inter-
mittent regimen [11]. Taken together these data support
the notion that intermittent dosing of VEGF TKIs might
enable administration of higher doses that could lead to
enhanced antitumor effects including higher response
rate and prolonged PFS.
Perfusion imaging with techniques such as arterial
spin labelled (ASL) MRI have shown utility as surrogate
markers for the effect of anti-angiogenic treatment in
preclinical models. Serial ASL MRI imaging and staged
tumor biopsies of established murine RCC xenografts
have shown that sorafenib administration produces
tumor necrosis in 3 days with associated loss of perfu-
sion [12]. Together, these models have established that
reperfusion occurs up to weeks in advance of actual
tumor regrowth. These studies provide rationale for
using ASL MRI to monitor the anti-angiogenic effects
associated with different doses and schedules of VEGFR
inhibitory therapies in xenograft models.
In the present work, we show that while continuous
administration of conventional dose sorafenib exhibits
antitumor activity in RCC, administration of a similar
total amount of drug as an increased dose on an inter-
mittent schedule results in improved anti-tumor effects
and that this benefit appears to be related to enhanced
antiangiogenic activity of the higher dose regimen.
Methods
Cell Culture
786-O cells (VHL deficient human renal cell carcinoma)
were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA) and were grown in RPMI
1640 medium from Cellgro. All media were supplemen-
ted with 2 mM L-glutamine, 10% fetal calf serum and
1% streptomycin (50 μg/ml) and cells were cultured at
37°C with 5% CO2.
Tumor xenograft induction
For the subcutaneous xenograft tumor model female
nude beige mice (Charles River Laboratories, MA), 6-8
weeks of age and 20 g average body weight, were used
as per [13]. The mice were housed and maintained in
laminar flow cabinets under specific pathogen-free con-
ditions. All experiments were approved by the Institu-
tional Animal Care and Use Committee at Beth Israel
Deaconess Medical Center. To produce tumors, renal
cancer cells were harvested from subconfluent cultures
by a brief exposure to 0.25% trypsin and 0.02% EDTA.
Trypsinization was stopped with medium containing
10% FBS, and the cells were washed once in serum-free
medium and resuspended in PBS. Only suspensions
consisting of single cells with greater than 90% viability
were used for the injections.
To establish RCC tumor xenograft, an established
human VHL deficient RCC cell line (786-O) was
injected subcutaneously (1 × 10
7 cells) into the flanks of
6-8 week old nude/beige mice. Tumors developed in >
80 percent of the mice and were usually visible within 2
weeks of implantation and once they reached a diameter
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size at the outset of treatment. Tumor long and short
axes were measured using calipers daily. Tumor volumes
were calculated with the formula volume = length ×
width
2/2 and followed to determine growth curves. Ani-
mals were euthanized according to IACUC guidelines
and treatment was terminated as experimentally
designed and described below. Prior to dissecting the
tumor, the midpoint of the cranial caudal axis of the
tumor was marked. This marked line matched the ASL
imaging slice. The tumor was cut into three equal seg-
ments parallel to the marked line. The mid segment of
the tumor was fixed in 10% formalin at room tempera-
ture for 24 hours prior to embedding in paraffin.
Tumors were sectioned and stained with H&E, and
immunohistochemical analysis.
Sorafenib dosing
Sorafenib tosylate (80 mg/kg daily 6 of 7 days per week
by gavage) was begun when the tumors had grown to a
diameter of 12 mm [14,15]. This 80 mg/kg dose was
based on a study by Chang et al. [16] in which four
doses of sorafenib (15, 30, 60 and 90 mg/kg; free base
equivalent) were compared in 786-O and RENCA xeno-
graft mice. They demonstrated similarity in the 60 and
90 mg/kg groups in terms of growth delay. The 60 mg/
kg free base dose, would convert to 82 mg/kg of the
tosylate form that was used in this study. This dose
(rounded to 80 mg/kg) was considered the maximally
effective dose. It was used in our prior studies with this
murine model [7] and was defined as the “conventional
dose” for current study. The “high dose intermittent”
regimen was 160 mg/kg administered 3 days on and 4
days off, “low dose intermittent” was 80 mg/kg adminis-
tered 3 days on and 4 days off, and “high dose continu-
ous” therapy was 160 mg/kg administered continuously.
The continuous conventional dose and the high dose
intermittent regimens delivered the same total dose of
sorafenib over 7 days (80 mg/kg/day given 6 out of 7
days per week and 160 mg/kg/day 3 days per week).
Mice were grouped randomly into treatment with
vehicle (n = 9), conventional dose continuous (n = 11),
high dose intermittent (n = 11), conventional dose inter-
mittent (n = 8), and high dose continuous (n = 4) by
gavage when the tumors reached 12 mm in diameter.
All animals were sacrificed and tumors were dissected
~36 days post therapy with the exception of vehicle
treated mice which were sacrificed when tumors
reached the mandated 20 mm sacrifice size (~22 days
post treatment). In addition, we sacrificed 6 mice on day
3 after treatment with high dose (n = 3) and conven-
tional dose (n = 3) for both the CD34 and CD31
analyses.
ASL MR imaging was performed on 6 mice prior at
baseline (day 0), day 3, day 7, and day 10 post treatment
with conventional dose continuous (n = 3) or high dose
intermittent (n = 3).
Immunohistochemistry
For CD34 analysis, 4 um thick sections were prepared
from formalin-fixed, paraffin-embedded tumor speci-
mens. Sections were deparaffinized, rehydrated and
heated with a pressure cooker to 125°C for 30 seconds
in citrate buffer for antigen retrieval. After cooling to
room temperature, sections were incubated in 3%
hydrogen peroxide for 5 minutes to quench endogenous
peroxidase, (Dako, Carpinteria, CA). The anti-CD34
antibody (Abcam, Cambridge, MA, Cat # AB-8158) was
applied at a 1:50 dilution, diluted with DaVinvi Green
diluent (BioCare Inc, Cat# PD900L), to sections for 1
hour, followed by rabbit anti-rat secondary antibody for
30 minutes. Detection was performed by incubating
with Dako EnVision+ System HRP labeled polymer anti-
rabbit for 30 minutes, followed by DAB chromogen.
Slides were scanned using the Scanscope XT (Aperio
Technologies Inc., Visa, CA) and analyzed using a modi-
fied Microvessel analysis algorithm (Aperio Technolo-
gies Inc).
For CD31 analysis, 4 um thick sections were prepared
from formalin-fixed, paraffin-embedded tumor speci-
mens. Sections were deparaffinized, rehydrated and
heated with a pressure cooker to 125°C for 30 seconds
in citrate buffer for antigen retrieval. After cooling to
room temperature, sections were incubated in 3%
hydrogen peroxide for 5 minutes to quench endogenous
peroxidase, (Dako, Carpinteria, CA). The anti-CD31
antibody (Abcam, Cambridge, MA, Cat #AB28364) was
applied at a 1:50 dilution, diluted with Dako antibody
diluent (Dako, Cat #S0809), to sections for 1 hour.
Detection was performed by incubating with Dako
EnVision+ System HRP labeled polymer anti-rabbit for
30 minutes, followed by DAB chromogen. Slides were
scanned using the Scanscope XT (Aperio Technologies
Inc., Visa, CA) and analyzed using a modified Microves-
sel analysis algorithm (Aperio Technologies Inc).
Tumor perfusion imaging
Tumor perfusion imaging (ASL MRI) was performed as
previously described [12]. Briefly mice were anaesthe-
tized, and placed in the supine position on a 3 cm in
diameter custom-built surface coil. Adhesive tape was
used to limit movement. Images were acquired using a
3.0 T whole-body clinical MRI scanner (3T HD; GE
Healthcare Technologies, Waukesha, WI). A single slice
ASL image was obtained with a single-short fast spin
echo sequence (SSFSE) using a background-suppressed,
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Twenty-four label and control pair images were
acquired and averaged for the ASL acquisition. A refer-
ence proton density image was acquired by turning off
all background suppression and labelling pulses in the
ASL preparation. T1 measurement was performed after
ASL imaging by using the same imaging sequence at
same slice location but with inversion recovery at differ-
ent inversion times. The single transverse slice of ASL
was carefully positioned at the center of the tumor,
which was marked on the skin with a permanent marker
pen for follow-up MRI studies. ASL sequence raw data
were saved and transferred to the analysis workstation
for image reconstruction by using custom software writ-
ten within the Interactive Data Language (IDL; ITT
v i s u a lI n f o r m a t i o nS o l u t i o n s ,B o u l d e r ,C O ) .T h eA S L
difference image, between average label and control
images, was then converted to quantitative tumor perfu-
sion as previously described [17].
Perfusion was calculated on a pixel-by-pixel basis, and
quantitative maps were produced. The quantitative
maps and the corresponding proton density reference
images were then analyzed by using Image J software
(Image Processing and Analysis in Java; National Insti-
tutes of Health, Bethesda, MD). To determine tumor
perfusion, a region of interest was drawn freehand
around the peripheral margin of the tumor by using an
electronic cursor on the reference image that was then
copied to the perfusion image. The mean blood flow for
the tumor tissue within the region of interest was
derived, and image window and level were fixed. A 16-
color table was applied in 10 mL/100 g/min increments
ranging from 0 to 160 mL/100 g/min, with flow values
represented as varying shades of black, blue, green, yel-
low, red, and purple, in order of increasing perfusion.
Statistical Analysis
All data were expressed as mean ± SEM. Statistical sig-
nificance of differences among groups of sorafenib dos-
ing response was calculated using one-way or two-way
analysis of variance (ANOVA). Tukey’s significant differ-
ence post hoc test was used for pairwise comparisons
after ANOVA to correct for multiple testing. The
groups among which P < 0.05 were considered signifi-
cantly different.
Results
High dose therapy is more effective in slowing tumor
growth than low dose therapy
We treated mice bearing 786-O tumor xenografts
(human VHL deficient renal cell carcinoma) on the 4
described treatment regimens: 1) Conventional dose
c o n t i n u o u s ,2 )h i g hd o s ei n t e r m i t t e n tt h e r a p y ,3 )c o n -
ventional dose intermittent therapy, and 4) high dose
continuous therapy. As shown in Figure 1, treatment
with high dose therapy slowed tumor growth to a
greater extent than conventional dose continuous or
intermittent dosing. The tumor size at the average day
that the control tumors reached their terminal sacrifice
size was lower in the high dose intermittent arm than in
the conventional dose continuous or intermittent arms
but not significantly different than the high dose contin-
uous arm. To assess relative stability in tumor growth,
the time to increase by 2 mm from pre-treatment size
w a sc a l c u l a t e da st h i si st h es m a l l e s tm e a s u r a b l e
increase in tumor size and roughly correlated to the
25% increase in tumor size used in RECIST schedule for
tumor progression. Table 1 shows that conventional
dose continuous sorafenib stabilized tumors for 9.3 +/-
1.7 days as compared to high dose intermittent (12.9 +/-
3.3 days, P < 0.05). The high dose intermittent did not
differ significantly from the high dose continuous. The
conventional dose intermittent arm showed inferior
anti-tumor effect with a 7.1 +/- 1.7 day time to increase
by 2 mm as compared to high dose intermittent and
conventional dose continuous regimens (P < 0.05). Fig-
ure 1B shows the average tumor size on the average day
of sacrifice of the vehicle treated tumors. The average
tumor size in the vehicle was (2188 +/- 142.6 mm
2), in
CD continuous (1372 +/- 103.7 mm
2), HD continuous
(769.1 +/- 57.82 mm
2), CD intermittent (1552 +/- 107.3
mm
2) and HD intermittent (1012 +/- 70.65 mm
2).
There was a significant difference in all groups including
vehicle vs all treatment arms, and CD continuous vs HD
intermittent (P < 0.05) except CD continuous vs CD
intermittent and HD intermittent vs HD continuous.
High dose sorafenib reduces tumor microvessel density
and perfusion
To determine the mechanism by which the higher dose
of sorafenib provided improved activity, we assessed
microvessel density (MVD) of the tumors by CD34 and
CD31 immunohistochemistry (IHC). Tumors were har-
vested after 3 days of treatment. Figure 2 shows that as
compared to vehicle treated tumors, the tumors exposed
to conventional and high dose sorafenib had lower
MVD (CD34 and CD31)(P < 0.01). There was a consis-
tent trend for lower MVD in the high dose treatment as
compared to the conventional dose treatment in both
the CD34 and CD31 analyses.
To understand the dynamic changes in tumor perfu-
sion over time, we performed serial imaging with ASL
MRI at day 0, 3, 7 and 10. As shown in Figure 3A, the
conventional dose of sorafenib lowered tumor perfusion
by 57% by day 3. Perfusion began to be restored by day
10 of therapy when the tumors were actively growing
despite continued treatment with sorafenib. In contrast,
high dose sorafenib lowered perfusion by 85% at day 3
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intermittent arm, tumor perfusion increased at day 7
(after a 4 day break in treatment) by 100% compared to
the nadir perfusion at day 3. At day 10, 3 days after sor-
afenib re-administration, tumor perfusion was signifi-
cantly lower in the high dose intermittent arm than in
the conventional dose continuous arm (p < 0.001). Fig-
ure 3B shows representative tumor perfusion images of
mice treated on conventional dose continuous or high
dose intermittent sorafenib at baseline, day 3, day7, and
day10 after treatment. Thus, the high dose intermittent
r e g i m e ns h o w e de n h a n c e da n dp r o l o n g e dd e c r e a s ei n
tumor perfusion relative to the conventional dose con-
tinuous and intermittent schedule.
Discussion
Sorafenib is a multi-kinase inhibitor that has activity in
RCC and hepatocellular cancer. The activity of sorafenib
in RCC is felt to be primarily due to its inhibition of
VEGFR2 on tumor endothelium resulting in antiangio-
geic effects. While sorafenib has activity in patients with
RCC, the median PFS associated with sorafenib treat-
ment appears to be less than that seen with more potent
inhibitors of the VEGFR2 pathway [18-21]. Data from
Amato et al, suggest that higher doses of sorafenib
might produce enhanced anti-tumor responses, but such
doses given continuously are not tolerable for most
patients with advanced RCC [2]. We investigated
increased sorafenib dose administered intermittently
(days 1-3 with 4 days break) in murine RCC xenograft
models given as a potential means of increasing the effi-
cacy of treatment without significant increase in toxicity.
Our experiments show that the high dose intermittent
regimen of sorafenib exhibited enhanced antitumor
activity compared to the conventional lower dose con-
tinuous schedule of sorafenib. Both regimens delivered
the same overall dose, but the intermittent schedule
allowed for a higher dose to be administered initially,
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Figure 1 Effects of dosing and schedule of sorafenib on tumor growth. Treatment was initiated when tumors reached 12 mm in long axis
(volume ~500 mm
3) with the administration of vehicle or different doses and schedule of sorafenib orally as indicated. All animals were
sacrificed and tumors were dissected ~36 days post treatment with the exception of vehicle treated mice which were sacrificed when tumors
reached the mandated 20 mm sacrifice size (~22 days post treatment, volume ~2500 mm
3). Figure 1A shows that treatment with high dose
intermittent therapy inhibited tumor growth to a greater extent than conventional dose continuous and intermittent therapy. Data are
presented as mean tumor volume with SEM. Figure 1B presents the tumor volume on the average day when vehicle treated tumors reached 20
mm in long axis (~22 days post treatment). The tumor volume of mice with high dose intermittent therapy is significantly smaller than that of
conventional dose continuous therapy (P < 0.05) while the volume did not differ in the high dose intermittent vs high dose continuous or
conventional dose intermittent vs conventional dose continuous arms (P > 0.05).
Table 1 Tumor growth by 2 mm
Treatment Vehicle
(N = 9)
CD continuous
(N = 11)
HD intermittent
(N = 11)
CD intermittent
(N = 8)
HD continuous
(N = 4)
Days to grow by 2 mm 6.2 ± 1.9 9.2 ± 1.7 12.9 ± 3.3 7.1 ± 1.7 16.8 ± 3.9
High dose intermittent therapy stabilized tumors longer as seen by the difference in the number of days for the tumors to increase by 2 mm in size. All armsa r e
significantly different (P < 0.05) except the conventional dose (CD) continuous vs CD intermittent, the CD intermittent vs vehicle and the high dose (HD)
intermittent vs HD continuous.
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studies in these animals suggested that this enhanced
antitumor effect was mediated by enhanced anti-angio-
genic effects associated with the higher dose and more
sustained anti-angiogenic activity with intermittent dos-
ing relative to continuous dosing.
Two factors may contributet ot h es u p e r i o r i t yo ft h e
high dose intermittent regimen. The higher dose led to a
greater reduction of tumor vessels and tumor perfusion
than the lower dose. However, the 4 day treatment-free
period did not compromise the efficacy of the high dose
intermittent regimen compared to high dose continuous
therapy. Thus, the treatment break was not detrimental.
During the 4 days off sorafenib, some tumor blood flow
returned, as the perfusion at day 7 was higher than day 3
in the high dose intermittent arm. Then, at day 10, blood
flow was again reduced after 3 more days of high dose
sorafenib. This is consistent with our prior work which
showed that tumors that develop resistance to sorafenib
exhibited restored ability to respond to sorafenib when
implanted into naïve hosts [22]. Further, our prior study
showed that even a few days off sorafenib ("drug holi-
day”) appeared to be sufficient to restore sensitivity of
RCC xenografts to sorafenib as measured by induction of
tumor necrosis. These observations are also supported by
clinical data that suggests restored sensitivity to VEGFR
TKI including the rechallenge with the same agent (suni-
tinib) following a drug holiday [23].
These data may have direct clinical relevance. Other
VEGFR pathway inhibitors have demonstrated similar
schedule issues. As recently reported, the EFFECT trial
showed that sunitinib given at 50 mg/day for 4 weeks fol-
lowed by a 2 week break was more active than sunitinib
37.5 mg daily with the higher dose intermittent regimen
showing a 9.9 month PFS vs a 7.1 month PFS for the
lower dose continuous regimen [11]. Furthermore, tivoza-
nib is administered at 1.5 mg/kg qd for 3 weeks out of 4
and has produced at response rate 30% and a median PFS
of 15 months in patients with clear cell histology who had
undergone a nephrectomy [18]. A recent dose escalation
study in RCC patients showed that increasing the dose of
sorafenib while maintaining the continuous dosing
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Figure 2 Microvessel density analysis of sorafenib treated tumors. Immunohistochemical analysis of CD31 (A-C) and CD34 (D-F) expression
in vehicle (A, D), low dose (B, E) and high dose (C, F) at day3 are shown. The bar graph shows the average CD31 and CD34 expression in the
vehicle (n = 3), conventional dose (n = 3), and high dose (n = 3) arms. As compared to vehicle treated tumors, the tumors exposed to
conventional and high dose sorafenib had lower MVD (CD34 and CD31)(P < 0.01). There was a consistent trend for lower MVD in the high dose
treatment as compared to the conventional dose treatment in both the CD34 and CD31 analyses.
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Page 6 of 8schedule was not feasible due to toxicities. However, the
patients in whom the dose could be escalated appeared to
have greater clinical benefit with longer PFS and greater
response rates [24]. Our data suggest that dose escalation
in addition to schedule alteration may improve efficacy
with less toxicity.
The concept that a higher dose may be more effective
is also consistent with a study by Houk et al which
showed that in patients treated with sunitinib, higher
blood levels of the drug correlated with longer PFS and
overall survival [3]. It is likely that the higher dose in
our study achieved a higher blood level in the mice. The
notion that higher drug levels may correlate with better
efficacy is further supported by the finding that hyper-
tension, thought to be an independent pharmacody-
namic marker of VEGFR inhibition, correlated with
response in a retrospective study of patients treated with
first or second-line sunitinib [4,5]. Patients with systolic
B P> / = 1 4 0h a da1 2 . 5m o n t hP F Sa n dp a t i e n t sw i t hn o
systolic hypertension had only a 2.5 month PFS.
Thus, as with other VEGFR pathway inhibitors, sorafe-
nib’s overall effect may be enhanced at higher doses,
likely leading to higher blood levels, and more effective
inhibition of VEGFR. This results in improved antian-
giogenic activity and improved efficacy. The finding that
the high dose showed similar activity at either an
intermittent or continuous schedule would support the
practice of allowing patients a break from therapy to
recover from toxicities. While this data requires valida-
tion, it suggests that the therapeutic index for VEGFR
TKI therapy of RCC may be maximal with higher dose
intermittent therapy. Perhaps using this approach might
optimize the impact of not just sorafenib and sunitinib,
but other VEGFR inhibitors in RCC and possibly in
other tumors that are responsive to VEGF targeted
therapy.
Conclusions
Sorafenib shows improved activity in RCC when admi-
nistered as a high dose intermittent regimen. The
mechanism by which this occurs appears to be
improved antiangiogenic activity. Considerations of dos-
ing and schedule of antiangiogenic agents may improve
their therapeutic function.
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Figure 3 Effect of dosing and schedule of sorafenib on tumor perfusion. Figure 3A shows normalized serial tumor perfusion from 3 mice at
4 time points. Conventional dose of sorafenib lowers tumor perfusion by 57% by day 3. This decrease begins to resume by day 10 of therapy. In
contrast, high dose intermittent sorafenib lowers perfusion by 85% at day 3. While tumor perfusion increases slightly at day 7 after there has
been a 4 day lapse in treatment, by day 10, tumor perfusion is still low (20% of pretreatment). Tumor perfusion was significantly different in two
arms at day 3 (P < 0.01) and day 10 (P < 0.001) as determined by two way ANOVA followed by Bonferroni posttest. Data are presented as mean
normalized tumor perfusion with SEM. Figure 3B, shows a representative set of serial tumor perfusion images from mice treated with a
conventional dose (upper row) or high dose intermittent (lower row) sorafenib. The blood flow values are shown in bold text are the values
obtained while the mice were on sorafenib and the values that are not in bold are from mice before or off therapy. The tumor size was
measured in long and short axes (mm) and the mean blood flow (mL/100 g/minute) are shown below each image. A color bar at the bottom
represents the range of perfusion values from 0 to 160 mL/100 g/minute.
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